Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro

Journal of Clinical Investigation

Volumn 102, Issue 1, 1998, Pages 223-231

  Oliva, Alessandra ^a   Kinter, Audrey L ^a   Vaccarezza, Mauro ^a   Rubbert, Andrea ^a   Catanzaro, Andrew ^a   Moir, Susan ^a   Monaco, JoAn ^a   Ehler, Linda ^a   Mizell, Stephanie ^a   Jackson, Robert ^a   Li, Yuexia ^b   Romano, Joseph W ^b   Fauci, Anthony S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

Author keywords

Chemokines; HIV; Human; Innate immunity; NK cells

Indexed keywords

CD16 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; INTERLEUKIN 2; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES;

ARTICLE; CONTROLLED STUDY; HOST RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0032128276     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI2323     Document Type: Article

References (58)

1. Trinchieri, G. 1989. Biology of natural killer cells. Adv. Immunol. 47: 187-376.
2. Pape, G., M. Troye, B. Axelsson, and P. Perlmann. 1979. Simultaneous occurrence of immunoglobulin-dependent and immunoglobulin-independent mechanisms in natural cytotoxicity of human lymphocytes. J. Immunol. 122: 2251-2260.
3. Moretta, A., C. Bottino, M. Vitale, D. Pende, R. Biassoni, M.C. Mingari, and L. Moretta. 1996. Receptors for HLA class-I molecules in human natural killer cells. Annu. Rev. Immunol. 14:619-648.
4. Lanier, L.L., and J.H. Phillips. 1996. Inhibitory MHC class I receptors on NK cells and T cells. Immunol. Today. 17:86-91.
5. Rungruengthanakit, K., A. Duerr, V. Suriyanon, L. Flowers, T. Nagachinta, A. Tansuhaj, D. Kunangern, M. de Boer, and K.E. Nelson. 1996. Immune parameters among highly exposed, persistently seronegative (HEPS) Thai women. Abstracts XI Int. Conference on AIDS. Mo.A.401a. (Abstr.) 1:13.
6. Shieh, T.M., D.L. Carter, K.R. Chadwick, J.B. Margolick, M.C. Zink, and J.E. Clements. 1998. Role of NK cells in control of acute SIV infection. Keystone Symposium-HIV Pathogenesis and Treatment. 102:4085a. (Abstr.)
7. Ratcliffe, L.T., P.T. Lukey, C.R. MacKenzie, and S.R. Ress. 1994. Reduced NK activity correlates with active disease in HIV-patients with multidrug-resistant pulmonary tuberculosis. Clin. Exp. Immunol. 97:373-379.
8. Brenner, B.G., M. Gornitsky, and M.A. Wainberg. 1994. Interleukin-2-inducible natural immune (lymphokine-activated killer cell) responses as a functional correlate of progression to AIDS. Clin. Diagn. Lab. Immunol. 1: 538-544.
9. Ahmad, A., and J. Menezes. 1995. Positive correlation between the natural killer and gp120/41-specific antibody-dependent cellular cytotoxic effector functions in HIV-infected individuals. J. Acquired Immune Defic. Syndr. 10: 115-119.
10. Moore, J.P., A. Trkola, and T. Dragic. 1997. Co-receptors for HIV-1 entry. Curr. Opin. Immunol. 9:551-562.
11. D'Souza, M.P., and V.A. Harden. 1996. Chemokines and HIV-1 second receptors. Confluence of two fields generates optimism in AIDS research. Nat. Med. 2:1293-1300.
12. + T cells. Science. 270:1811-1815.
13. Deng, H., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Di Marzio, S. Marmon, R.E. Sutton, C.M. Hill, et al. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 381:661-666.
14. + cells is mediated by the chemokine receptor CC-CKR-5. Nature. 381:667-673.
15. Alkhatib, G., C. Combadiere, C. Broder, Y. Feng, P. Kennedy, P. Murphy, and E.A. Berger. 1996. CC-CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 272:1955-1958.
16. Choe, H., M. Farzan, Y. Sun, N. Sullivan, B. Rollins, P.D. Ponath, L. Wu, C.R. Mackay, G. LaRosa, W. Newman, et al. 1996. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 85:1135-1138.
17. Doranz, B.J., J. Rucker, Y. Yi, R.J. Smyth, M. Samson, S.C. Peiper, M. Parmentier, R.G. Collman, and R.W. Doms. 1996. A dual-tropic primary HIV-1 isolate that uses fusin and the B-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell. 85:1149-1158.
18. Liu, R., W.A. Paxton, S. Choe, D. Ceradini, S.R. Martin, R. Horuk, M.H. MacDonald, H. Stuhlmann, R.A. Koup, and N.R. Landau. 1996. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 86:367-377.
19. Samson, M., F. Libert, B.J. Doranz, J. Rucker, C. Liesnard, C.M. Farber, S. Saragosti, C. Lapoumeroulie, J. Cognaux, C. Forceille, et al. 1996. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 382:722-725.
20. Eugen-Olsen, J., A.K. Iversen, P. Garred, U. Koppelhus, C. Pedersen, T.L. Benfield, A.M. Sorensen, T. Katzenstein, E. Dickmeiss, J. Gerstoft, et al. 1997. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS. 11:305-310.
21. Dean, M., M. Carrington, C. Winkler, G.A. Huttley, M.W. Smith, R. Allikmets, J.J. Goedert, S.P. Buchbinder, E. Vittinghoff, E. Gomperts, et al. 1996. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science. 273:1856-1862.
22. Huang, Y., W.A. Paxton, S.M. Wolinsky, A.U. Neumann, L. Zhang, T. He, S. Kang, D. Ceradini, Z. Jin, K. Yazdanbakhsh, et al. 1996. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat. Med. 2:1240-1243.
23. Michael, N.L., G. Chang, L.G. Louie, J.R. Mascola, D. Dondero, D.L. Birx, and H.W. Sheppard. 1997. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat. Med. 3:338-340.
24. Bluman, E.M., K.J. Bartynski, B.R. Avalos, and M.A. Caligiuri. 1996. Human natural killer cells produce abundant macrophage inflammatory protein-1 alpha in response to monocyte-derived cytokines. J. Clin. Invest. 97:2722-2727.
25. ™ isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection. J. Virol. Methods. 35:273-286.
26. Romano, J.W., K.G. Williams, R.N. Shurtliff, C. Ginocchio, and M. Kaplan. 1997. NASBA technology: isothermal RNA amplification in qualitative and quantitative diagnostics. Immunol. Invest. 26:15-28.
27. Willey, R.L., D.H. Smith, L.A. Lasky, T.S. Theodore, P.L. Earl, B. Moss, D.J. Capon, and M.A. Martin. 1988. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J. Virol. 62:139-147.
28. Zack, J.A., S.J. Arrigo, S.R. Weitsman, A.S. Go, A. Haislip, and I.S.Y. Chen. 1990. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell. 61:213-222.
29. Trinchieri, G., and N. Valiante. 1993. Receptors for the Fc fragment of IgG on natural killer cells. Nat. Immun. 12:218-234.
30. van Lier, R.A., M. Brouwer, V.I. Rebel, C.J. van Noesel, and L.A. Aarden. 1989. Immobilized anti-CD3 monoclonal antibodies induce accessory cell-independent lymphokine production, proliferation and helper activity in human T lymphocytes. Immunology. 68:45-50.
31. Trinchieri, G., M. Matsumoto-Kobayashi, S.C. Clark, J. Seehra, L. London, and B. Perussia. 1984. Response of resting human peripheral blood natural killer cells to interleukin 2. J. Exp. Med. 160:1147-1169.
32. Robertson, M.J., R.J. Soiffer, S.F. Wolf, T.J. Manley, C. Donahue, D. Young, S.H. Herrmann, and J. Ritz. 1992. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J. Exp. Med. 175:779-788.
33. Carson, W.E., J.G. Giri, M.J. Lindemann, M.L. Linett, M. Ahdieh, R. Paxton, D. Anderson, J. Eisenmann, K. Grabstein, and M.A. Caligiuri. 1994. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med. 180:1395-1403.
34. + lymphocytes can control HIV infection in vitro by suppressing virus replication. Science. 234:1563-1566.
35. + T cell-derived soluble factor(s), but not beta-chemokines RANTES, MIP-1 alpha, and MIP-1 beta, suppress HIV-1 replication in monocyte/macrophages. Proc. Natl. Acad. Sci. USA. 93:15341-15345.
36. + T cells. Immunol. Today. 17:217-224.
37. + cells in human immunodeficiency virus type I pathogenesis: cytolytic and noncytolytic inhibition of viral replication. Adv. Immunol. 66:273-311.
38. Ruscetti, F.W., J.A. Mikovits, V.S. Kalyanaraman, R. Overton, H. Stevenson, K. Stromberg, R.B. Herberman, W.L. Farrar, and J.R. Ortaldo. 1986. Analysis of effector mechanisms against HTLV-I-and HTLV-III/LAV-infected lymphoid cells. J. Immunol. 136:3619-3624.
39. + T cells of HIV-infected individuals is regulated by a balance between the viral suppressive effects of endogenous beta-chemokines and the viral inductive effects of other endogenous cytokines. Proc. Natl. Acad. Sci. USA. 93:14076-14081.
40. Verani, A., G. Scarlatti, M. Comar, E. Tresoldi, S. Polo, M. Giacca, P. Lusso, A.G. Siccardi, and D. Vercelli, 1997. C-C chemokines released by lipopolysaccharide (LPS)-stimulated human macrophages suppress HIV-1 infection in both macrophages and T cells. J. Exp. Med. 185:805-816.
41. + T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele. J. Exp. Med. 186: 455-160.
42. Zagury, D., A. Lachgar, V. Chams, L.S. Fall, J. Bernard, J.-F. Zagury, B. Bizzini, A. Gringeri, E. Santagostino, J. Rappaport, et al. 1998. C-C chemokines, pivotal in protection against HIV type 1 infection. Proc. Natl. Acad. Sci. USA. 95:3857-3861.
43. Scala, E., G. D'Offizi, R. Rosso, O. Turriziani, R. Ferrara, A.M. Mazzone, G. Antonelli, F. Aiuti, and R. Paganelli. 1997. C-C chemokines, IL-16, and soluble antiviral factor activity are increased in cloned T cells from subjects with long-term non-progressive HIV infection. J. Immunol. 158:4485-4492.
44. +, T-cell clones correlates with the clinical state of human immunodeficiency virus type 1 (HIV-1)-infected individuals and may be responsible for blocking infection with non-syncytium-inducing HIV-1 in vitro. J. Virol. 72:876-881.
45. Wagner, L., O.O. Yang, E.A. Garcia-Zepeda, Y. Ge, S.A. Kalams, B.D. Walker, M.S. Pasternack, and A.D. Luster. 1998. Beta-chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans. Nature. 391:908-911.
46. Jewett, A., X.H. Gan, L.T. Lebow, and B. Bonavida. 1996. Differential secretion of TNF-alpha and IFN-gamma by human peripheral blood-derived NK subsets and association with functional maturation. J. Clin. Immunol. 16: 46-54.
47. Moriuchi, H., M. Moriuchi, and A.S. Fauci. 1997. Nuclear factor-kappa B potently upregulates the promoter activity of RANTES, a chemokine that blocks HIV infection. J. Immunol. 158:3483-3491.
48. Nelson, P.J., B.D. Ortiz, J.M. Pattison, and A.M. Krensky. 1996. Identification of a novel regulatory region critical for expression of the RANTES chemokine in activated T lymphocytes. J. Immunol. 157:1139-1148.
49. Anegon, I., M.C. Cuturi, G. Trinchieri, and B. Perussia. 1988. Interaction of Fcγ receptor (CD16) with ligands induces transcription of IL-2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. J. Exp. Med. 167:452-472.
50. Lane, H.C., H. Masur, L. Edgard, G. Whalen, A. Rook, and A.S. Fauci. 1983. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 309:453-458.
51. Rook, A.M., H.C. Lane, T. Folks, S. McCoy, H. Alter, and A.S. Fauci. 1987. Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells. J. Immunol. 138:1064-1067.
52. + cell function down-regulation in AIDS patients. J. Immunol. 148:2709-2716.
53. Kovacs, J.A., S. Vogel, J.M. Albert, J. Falloon, R.T. Davey, Jr., R.E. Walker, M.A. Polis, K. Spooner, J.A. Metcalf, M. Baseler, et al. 1996. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N. Engl. J. Med. 335:1350-1356.
54. Clerici, M., D.R. Lucey, J.A. Berzofsky, L.A. Pinto, T.A. Wynn, S.P. Blatt, M.J. Dolan, C.W. Hendrix, S.F. Wolf, and G.M. Shearer. 1993. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science. 262:1721-1724.
55. Chehimi, J., J.D. Marshall, O. Salvucci, I. Frank, S. Chehimi, S. Kawecki, D. Bacheller, S. Rifat, and S. Chouaib. 1997. IL-15 enhances immune functions during HIV infection. J. Immunol. 158:5978-5987.
56. Schwartz, D.H., G. Skowron, and T.C. Merigan. 1991. Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus. J. Acquired Immune Defic. Syndr. 4:11-23.
57. De Paoli, P., S. Zanussi, C. Simonelli, M.T. Bortolin, M. D'Andrea, C. Crepaldi, R. Talamini, M. Comar, M. Giacca, and U. Tirelli. 1997. Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro production in HIV+ subjects. J. Clin. Invest. 100:2737-2743.
58. Pal, R., A. Garzino-Demo, P.D. Markham, J. Burns, M. Brown, R.C. Gallo, and A.L. DeVico. 1997. Inhibition of HIV-1 infection by the β-chemokine MDC. Science. 278:695-698.